Trial Search Results
Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia
The primary goal of this study is to evaluate the safety and efficacy of two different dosing regimens of an investigational drug called Avexitide in treating low blood sugar in patients with Acquired Hyperinsulinemic Hypoglycemia.
Stanford is currently accepting patients for this trial.
Dr. Tracey McLaughlin, MD
Collaborator: Eiger BioPharmaceuticals
- Drug: Avexitide
- History of bariatric or upper-gastrointestinal surgery (RYGB, VSG, gastrectomy,
esophagectomy, or Nissen fundoplication) at least 12 months prior to the start of
- History of recurrent hypoglycemia occurring after bariatric or upper-GI surgery, as
documented in the medical record.
- Body mass index (BMI) of up to 40 kg/m2
- If female, must not be breastfeeding and must have a negative urine pregnancy test
- Major surgery within 6 months before randomization.
- History of or current hyperinsulinism other than Acquired Hyperinsulinism (e.g.,
insulin autoimmune hypoglycemia).
- Use of agents that may interfere with glucose metabolism
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study